SBIR Phase I: A Novel SARS-CoV-2 Virus-Like Particle Optimized to Deliver shRNA Therapeutics to Prevent and Treat Infection (COVID-19)

这个小企业创新研究第一阶段项目的更广泛的影响/商业潜力包括产生一种新的疗法来对抗新冠肺炎大流行，同时也为治疗呼吸道感染和肺部疾病的新方法奠定基础。这种方法依赖于精确的治疗方法，这种治疗方法可以削弱新冠肺炎病毒形成感染性颗粒的能力。在未来，这种方法可能会被迅速修改，以用于对抗其他呼吸道病毒或提供其他肺部药物。这个小型企业创新研究(SBIR)第一阶段项目寻求通过精确地提供基因组药物并与SARS-CoV-2病毒直接竞争进入高危或受感染的肺上皮细胞来产生一种新的SARS-CoV-2治疗方法。该项目将使用硅胶方法来设计和确定产品的优先顺序，然后进行体外测试和验证。该项目旨在优先考虑一种新的递送工具和候选基因组医学。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project involves generation of a new class of therapeutics to combat the COVID-19 pandemic, while also laying the foundation for a new way to treat respiratory infection and pulmonary illness. This approach relies on precise delivery of a treatment that impairs the ability of the COVID-19 virus to form infectious particles. In the future, this approach could be rapidly modified for use against other respiratory viruses or to deliver other pulmonary medicines. This Small Business Innovation Research (SBIR) Phase I project seeks to generate a novel SARS-CoV-2 therapeutic through precise delivery of a genomic medicine and direct competition with the SARS-CoV-2 virus for access to at-risk or infected pulmonary epithelial cells. This project will use an in silico approach to design and prioritize the product, followed by in vitro testing and validation. This project aims to prioritize a novel delivery vehicle and genomic medicine candidate.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.